Our findings also align with Nociti et al. (2019) [40], who proposed that epigenetic modifications in the BDNF gene, including methylation patterns associated with the Val66Met polymorphism, could be indicative of disease progression and symptom severity in MS. Here, BDNF is linked to myeloid sarcoma.